marked.bio

PD-1/VEGF bispecific antibody · bispecific antibody

JS207

1 active trials across 8 of our biomarkers, targeting PD-1 x VEGF. Not approved for any biomarker on marked.bio yet.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
ALK fusion 1 1 Phase 2
BRAF V600E 1 1 Phase 2
EGFR exon 19 deletion / L858R 1 1 Phase 2
HER2 (ERBB2) activating mutation 1 1 Phase 2
KRAS G12C 1 1 Phase 2
NTRK1/2/3 fusion 1 1 Phase 2
RET fusion or mutation 1 1 Phase 2
ROS1 fusion 1 1 Phase 2

Trials

1 of 1 trials shown

  1. Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI Therapy

    Recruiting Phase 2 Shanghai Junshi Bioscience Started 2025Primary completion 2026-09 NCT06868836

    JS207pemetrexedcarboplatincisplatinJS212

    … exon G719X mutation, 19 exon deletion mutation, 20 exon S768I or T790M mutation, 21 exon L858R or L861Q mutation), ALK fusion, ROS1 fusion, BRAF V600E mutation, NTRK fusion, MET14 exon…

    EGFR exon 19 deletion / L858RKRAS G12CBRAF V600EHER2 (ERBB2) activating mutationALK fusionROS1 fusionRET fusion or mutationNTRK1/2/3 fusionNon-squamous Non-small Cell Lung Cancer